Drug Profile
Research programme: viral disease therapies - Merck
Latest Information Update: 02 Mar 2021
Price :
$50
*
At a glance
- Originator Sunesis Pharmaceuticals
- Developer Merck & Co
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in USA (PO)
- 13 Feb 2008 This programme is still in active development